Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
Evan J. Lipson, Ragini R. Kudchadkar, Sunil Reddy, Tomoko Akaike, Thomas Olencki, William H. Sharfman, Philip Friedlander, Steven P. Fling, Mizuho Kalabis, Candice D. Church, Kari Kendra, Michi M. Shinohara, Adil Daud, Adam I. Riker, Harriet M. Kluger, Elad Sharon, Melissa Amber Burgess, Janis M. Taube, Paul Nghiem, Brent A. Hanks, Suzanne L. Topalian, Blanca Homet Moreno, Andrew S. Brohl, Brian C. Boulmay, Martin A. Cheever, Bob Salim, Erin Jensen, Shailender Bhatia, Nirasha Ramchurren
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
BackgroundMerkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current stud
Autor:
Jacques Galipeau, Jiusheng Deng, Andrea Pennati, Ragini R. Kudchadkar, David H. Lawson, Shala Yuan
Publikováno v:
Journal for Immunotherapy of Cancer
Melanoma is the most dangerous type of skin cancer and one of the fastest growing cancers in the USA. Immunotherapy, by enhancing patient's immune system, has become an attractive approach for melanoma treatment due to the rapid drug resistance to ch
Autor:
Evan J. Lipson, Nageatte Ibrahim, Janice M. Mehnert, Kristen Spencer, Keisuke Shirai, Heddy Bartell, Ragini R. Kudchadkar, David H. Lawson, Jason J. Luke, Sowmya Ravi, Mary Ruisi, Ngoc Thi Gunter, John A. Thompson
Publikováno v:
Journal for Immunotherapy of Cancer
Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that has demonstrated a survival benefit and durable disease control in patients with advanced melanoma. Ipilimumab is associated with potenti